

Cardiovascular Disease
 Hath6: A Novel Transcription Factor Modulating Endothelial Phenotype.
 Principal Investigator
 2004-2006 National Institutes of Health 1 KO8 HL076191
 Hath6: A Link Between Flow and Endothelial Phenotype
 Principal Investigator Mentor: Thomas Quertermous, M.D.

Employment history:Industry positions:

2005-2006 *Associate Director*, Global Development
 Global Development Leader, Aranesp® New Indications (Heart Failure)
 General Medicine Therapeutic Area
 Amgen, Thousand Oaks, CA

2006-2006 *Director*, Global Development
 Global Development Leader, Aranesp® New Indications (Heart Failure)
 General Medicine Therapeutic Area
 Amgen, Thousand Oaks, CA

2006-2007 *Executive Director*, Global Development
 Global Development Leader, Aranesp® New Indications (Heart Failure)
 and AMG 423 (omecamtiv mecarbil)
 General Medicine Therapeutic Area
 Amgen, Thousand Oaks, CA

2007-2010 *Executive Director*, Global Development
 Global Development Leader, AMG 423 (omecamtiv mecarbil) and AMG
 785 (romosozumab)
 General Medicine-Inflammation and Bone Therapeutic Areas
 Amgen, Thousand Oaks, CA

2010-2012 *Executive Director*, Global Development
 Global Development Leader, AMG 423 (omecamtiv mecarbil) and AMG
 145 (evolocumab)
 Global Project Area Leader, Cardiovascular
 Cardiovascular Therapeutic Area
 Amgen, Thousand Oaks, CA

2012-2014 *Executive Director*, Global Development
 Global Development Leader, AMG 145 (evolocumab)
 Global Project Area Leader, Cardiovascular
 Cardiovascular Therapeutic Area
 Amgen, Thousand Oaks, CA

2014-2014 *Executive Director*, Global Development
 Global Project Area Leader, Cardiovascular and Metabolic
 Cardiovascular and Metabolic Therapeutic Areas
 Amgen, Thousand Oaks, CA

2015-2016 *Vice President*, Global Development
 Head, Cardiovascular and Metabolic Therapeutic Areas
 Amgen, Thousand Oaks, CA

2016-2017 *Vice President*, Global Development
 Head, Cardiovascular and Metabolic Therapeutic Areas and Development
 Design Center
 Amgen, Thousand Oaks, CA

2017-present *Vice President*, Global Development
 Head, Cardiovascular, Metabolic, and Neuroscience Therapeutic Areas
 Amgen, Thousand Oaks, CA

Academic positions:

2004-2005 *Staff Physician*, Division of Cardiology
 Veterans Administration Health Care System
 Palo Alto Division, Palo Alto, CA

2004-2006 *Instructor*, Division of Cardiovascular Medicine
 Stanford University Hospital and Clinics, Stanford, CA

Clinical positions:

1999-2001 *Pool Physician*, Department of Internal Medicine
 The Permanente Medical Group, Inc., Milpitas, CA

1999-2004 *Medical Staff*, Veterans Administration Health Care System
 Menlo Park Division, Menlo Park, CA

1999-2004 *Medical Staff*, Veterans Administration Health Care System
 Palo Alto Division, Palo Alto, CA

2000-2005 *Medical Staff*, Cardiology
 Mills Peninsula Hospital, Burlingame, CA

Publications

Peer-reviewed articles

1. Topper JN, **Wasserman SM**, Anderson KR, Cai J, Falb D, and Gimbrone MA, Jr. Expression of the bumetanide-sensitive Na-K-Cl cotransporter BSC2 is differentially regulated by fluid mechanical and inflammatory cytokine stimuli in vascular endothelium. *J Clin Invest.* 1997 Jun15;99(12): 2941-2949.
2. **Wasserman SM**, Fann JI, Atwood E, Burdon TA, Fadel BM. Acquired left ventricular-right atrial communication (Gerbode-type defect). *Echocardiography.* 2002 Jan;19(1) :67-72.
3. Yang R-B, Ng DCK, **Wasserman SM**, Colman SD, Shenoy S, Mehraban F, Komuves LG, Tomlinson JE, and Topper JN. Identification of a novel family of cell-surface proteins expressed in human vascular endothelium. *J Biol Chem.* 2002 Nov 29;277(48): 46364-47373. Epub 2002 Sep 21.
4. **Wasserman SM**, Mehraban F, Komuves LG, Yang R-B, Tomlinson JE, Spriggs F, Hwang S, Topper JN. Gene expression profile of human endothelial cells exposed to sustained fluid shear stress. *Physiol Genomics.* 2002 Dec 26;12(1): 13-23. Epub 2002 Dec 26.
5. Yang RB, Ng DCK, **Wasserman SM**, Komuves LG, Gerritsen ME and Topper JN. A novel IL-17 receptor-like protein expressed on human endothelial cells antagonizes basic fibroblast growth factor-induced signaling. *J Biol Chem.* 2003 Aug 29;278(35): 33232-33238. Epub 2003 Jun 12.
6. **Wasserman SM**, Topper JN. Adaptation of endothelium to flow: *in vitro* analyses and *in vivo* implications. *Vasc Med* 2004 Feb;9(1): 35-45.

7. Wu BT, Su YH, Tsai MT, **Wasserman SM**, Topper JN and Yang RB. A novel secreted, cell-surface glycoprotein containing multiple EGF-like repeats and one CUB domain is highly expressed in human osteoblasts. *J Biol Chem.* 2004 Sep 3;279(36): 37485-37490. Epub 2004 Jul 2.
8. Ponikowski P, Anker SD, Szachniewicz J, Okonko D, Ledwidge M, Zymlinski R, Ryan E, **Wasserman SM**, Baker N, Rosser D, Rosen SD, Poole-Wilson PA, Banasiak W, Coats AJS, DM, McDonald K. Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. *J Am Coll Cardiol.* 2007 Feb 20;49(7); 753-762. Epub 2007 Feb 5. Epub 2007 Aug 6.
9. van Veldhuisen DJ, Dickstein K, Cohen-Solal A, Lok DJA, **Wasserman SM**, Baker N, Rosser D, Cleland JGF, Ponikowski P. A randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anemia. *Eur Heart J.* 2007 Sep; 28(18): 2208-2216. Epub 2007 Aug 6.
10. Patel H, Ekman I, Spertus JA, **Wasserman SM**, Persson L-O. Psychometric properties of a Swedish version of the Kansas City Cardiomyopathy Questionnaire in a chronic heart failure population. *Eur J Cardiovasc Nurs.* 2008 Sep;7(3): 214-221. Epub 2007 Dec 3.
11. Ghali JK, Anand IS, Abraham WT, Fonarow GC, Greenberg B, Krum H, Massie BM, **Wasserman SM**, Trotman M-L, Sun Y, Knusel B, Armstrong P. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. *Circulation.* 2008 Jan 29;117(4): 526-535. Epub 2008 Jan 14.
12. Nguyen P, **Wasserman SM**, Kim J, Fann J, Giacomini J. Initial report of successful lysis of an aortic prosthetic valve thrombosis using a dosing regimen for peripheral artery and bypass graft occlusions. *J Thorac Cardiovasc Surg Thorac Cardiovasc Surg.* 2008 Mar;135(3): 691-693.
13. Van Veldhuisen DJ, **Wasserman SM**, Baker N. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia: Reply. *Eur Heart J.* 2008;29(4): 566-567.
14. McMurray JJV, Anand IS, Diaz R, Maggioni AP, O'Connor C, Pfeffer MA, Polu KR, Solomon SD, Sun Y, Swedberg K, Tendera M, van Veldhuisen DJ, **Wasserman SM**, Young JB. Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a phase III, anaemia-correction, morbidity-mortality trial. *Eur J of Heart Fail.* 2009 Aug;11(8): 795-801. Erratum in: *Eur J Heart Fail.* 2010 Jul;12(7):765
15. Klapholz M, Abraham WT, Ghali JK, Ponikowski P, Anker SA, Knusel B, Sun Y, **Wasserman SM**, van Veldhuisen DJ. The safety and tolerability of darbepoetin alfa in patients with anemia and symptomatic heart failure. *Eur J Heart Fail.* 2009 Nov;11(11): 1071-1077.
16. Abraham WT, Anand IS, Klapholz M, Ponikowski P, Chou W, Sun Y, **Wasserman SM**, van Veldhuisen DJ. Treatment of anemia with darbepoetin alfa in patients with heart failure. *Congestive Heart Failure.* 2010 May-Jun;16(3): 87-95.
17. Cleland JGF, Teerlink JR, Senior R, Nifontov EM, McMurray JJV, Lang CC, Tsyrlin VA, Greenberg B, Mayet J, Francis F, Shaburishvili T, Monaghan M, Saltzberg M, Neyses L,

- Lee JH, Saikali KG, Clarke CP, Goldman JH, **Wasserman SM**, Wolff AA, Malik FI. The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. *Lancet*. 2011 Aug 20; 378(9792): 676-683.
18. Kohli P, Desai NR, Giugliano RP; Kim JB, Somaratne R, Huang F, Knusel B, McDonald S, Abrahamsen T, **Wasserman SM**, Scott R, Sabatine, MS. Design and rationale of the LAPLACE-TIMI 57 trial: A phase II, double-blind, placebo-controlled study of the efficacy and tolerability of a monoclonal antibody inhibitor of PCSK9 in subjects with hypercholesterolemia on background statin therapy. *Clin Cardiol*. 2012; 35(7): 385-391. Epub 2012 Jun 19.
 19. Dias CS, Shaywitz AJ, **Wasserman SM**, Smith BP, Gao B, Stolman DS, Crispino CP, Smirnakis KV, Emery MG, Colbert A, Gibbs JP, Retter MW, Cooke BP, Uy ST, Matson M, Stein EA. Effects of AMG 145 on low-density lipoprotein cholesterol levels: Results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. *J Am Coll Cardiol* 2012 Nov 6; 60(19): 1888-1898. Epub 2012 Oct 17.
 20. Sullivan D, Olsson AG, Scott R, Kim JB, Xue A, GebSKI V, **Wasserman SM**, Stein EA. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. *JAMA*. 2012 Dec 19;308(23): 2497-2506.
 21. Raal F, Scott R, Somaratne R, Bridges I, Li G, **Wasserman SM**, Stein EA. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the reduction of LDL-C with PCSK9 inhibition in heterozygous familial hypercholesterolemia disorder (RUTHERFORD) randomized trial. *Circulation*. 2012 Nov 13;126(20): 2408-2417. Epub 2012 Nov 5.
 22. Koren MJ, Scott R, Kim JB, Knusel B, Liu T, Lei L, Bolognese M, **Wasserman SM**. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. *Lancet*. 2012 Dec 8; 380(9858): 1995-2006. Epub 2012 Nov 6.
 23. Giugliano RP, Desai NR, Kohli P, Rogers WJ, Somaratne R, Huang F, Liu T, Mohanavelu S, Hoffman EB, McDonald ST, Abrahamsen TE, **Wasserman SM**, Scott R, Sabatine MS; LAPLACE-TIMI 57 Investigators. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. *Lancet*. 2012 Dec 8; 380(9858): 2007-17. Epub 2012 Nov 6.
 24. Stein EA, **Wasserman SM**, Dias C, Scott R, Raal F. AMG 145. *Drugs of the Future*. 2013;38(7): 451-459.
 25. LaRosa JC, Pedersen TR, Somaratne R, **Wasserman SM**. Safety and effect of very low levels of low-density lipoprotein cholesterol on cardiovascular events. *Am J Cardiol*. 2013 Apr 15; 111(8): 1221-1229. Epub 2013 Jan 30.

26. Foltz IN, Karow M, **Wasserman SM**. Evolution and emergence of therapeutic monoclonal antibodies - What cardiologists need to know. *Circulation*. 2013 Jun 4; 127: 2222-2230.
27. Zannad F, Garcia AA, Anker SD, Armstrong PW, Calvo G, Cleland JG, Cohn JN, Dickstein K, Domanski MJ, Ekman I, Filippatos GS, Gheorghiade M, Hernandez AF, Jaarsma T, Koglin J, Konstam M, Kupfer S, Maggioni AP, Mebazaa A, Metra M, Nowack C, Pieske B, Piña IL, Pocock SJ, Ponikowski P, Rosano G, Ruilope LM, Ruschitzka F, Severin T, Solomon S, Stein K, Stockbridge NL, Stough WG, Swedberg K, Tavazzi L, Voors AA, **Wasserman SM**, Woehrle H, Zalewski A, McMurray JJ. Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. *Eur J Heart Fail*. 2013 Oct; 15(10): 1082-1094. Epub 2013 Jun 19.
28. Desai NR, Kohli P, Giugliano RP, O'Donoghue M, Somaratne R, Zhou J, Hoffman E, Huang F, Rogers WJ, **Wasserman SM**, Scott R, Sabatine MS. AMG 145, a monoclonal antibody against PCSK9, significantly reduces lipoprotein (a) in hypercholesterolemic patients receiving statin therapy: An analysis from the LAPLACE-TIMI 57 trial. *Circulation*. 2013 Aug 27;128(9): 962-969. Epub 2013 Oct 23.
29. Stein EA, Honarpour N, **Wasserman SM**, Xu F, Scott R, Raal FJ, MB, BCh, Effect of the PCSK9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. *Circulation*. 2013 Nov 5;128(19): 2113-2120. . Epub 2013 Sep 6.
30. Bhandari M, **Wasserman SM**, Yurgin N, Petrisor B, Sprague S, Ricardo E, Dent RE. The development and preliminary validation of a functional index for intramedullary nailed tibial fractures (FIX-IT). *Can J Surg*. 2013 Oct; 56(5): E114-20.
31. Desai NR, Giugliano RP, Zhou J, Kohli P, Somaratne R, Hoffman E, Liu T, Scott R, **Wasserman SM**, Sabatine MS. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin therapy-thrombolysis in myocardial infarction 57). *J Am Coll Cardiol*. 2014 Feb 11;63(5): 430-433. Epub 2013 Oct 23.
32. Koren MJ, Giugliano RP, Raal FJ, Sullivan D, Bolognese M, Langslet G, Civeira F, Somaratne R, Nelson P, Liu T, Scott R, **Wasserman SM**, Sabatine MS; OSLER Investigators. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the open-label study of long-term evaluation against LDL-C (OSLER) randomized trial. *Circulation*. 2014 Jan 14;129(2): 234-243. Epub 2013 Nov 19.
33. McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, Langdahl BL, Reginster J-Y, Zanchetta JR, **Wasserman SM**, Katz L, Maddox J, Yang Y-C, Libanati C, Bone HG. Romosozumab in postmenopausal women with low bone mineral density. *N Engl J Med*. 2014 Jan 30;370(5): 412-420. Epub 2014 Jan 1.
34. Fang F, **Wasserman SM**, Torres-Vazquez J, Weinstein B, Cao F, Li Z, Wilson KD, Yue W, Wu JC, Xie X, Pei X. The role of Hath6, a newly identified shear-stress-responsive transcription factor, in endothelial cell differentiation and function. *J Cell Sci*. 2014 Apr 1;127(Pt 7): 1428-1440. Epub 2014 Jan 24.

35. Cho L, Rocco M, Colquhoun D, Sullivan D, Rosenson RS, Dent R, Xue A, Scott R, **Wasserman SM**, Stroes E. Design and rationale of the GAUSS-2 study trial: a double-blind, ezetimibe-controlled phase 3 study of the efficacy and tolerability of evolocumab (AMG 145) in subjects with hypercholesterolemia who are intolerant of statin therapy. *Clin Cardiol*. 2014 Mar;37(3): 131-139. Epub 2014 Jan 29.
36. Robinson JG, Rogers WJ, Nedergaard BS, Fialkow J, Neutel JM, Ramstad D, Somaratne R, Legg JC, Nelson P, Scott R, **Wasserman SM**, Weiss R. Rationale and design of LAPLACE-2: A phase 3, randomized, double-blind, placebo- and ezetimibe-controlled trial evaluating the efficacy and safety of evolocumab in subjects With hypercholesterolemia on background statin therapy. *Clin Cardiol*. 2014 Apr;37(4): 195-203. Epub 2014 Jan 30.
37. Raal FJ, Giugliano RP, Sabatine MS, Koren MJ, Langslet G, Bays H, Blom D, Eriksson M, Dent, R, **Wasserman SM**, Huang F, Xue A, Albizem M, Scott R, Stein EA. Reduction in lipoprotein (a) with the PCSK9 monoclonal antibody evolocumab (AMG 145): A pooled analysis of over 1,300 patients in 4 phase 2 trials. *J Am Coll Cardiol*. 2014 Apr 8;63(13): 1278-1288. Epub 2014 Feb 5.
38. Stein EA, Giugliano RP, Koren MJ, Raal FJ, Roth EM, Weiss R, Sullivan D, **Wasserman SM**, Somaratne R, Kim JB, Yang J, Liu T, Albizem M, Scott R, Sabatine MS; PROFICIO Investigators. Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials. *Eur Heart J*. 14 Sep 1;35(33): 2249-2259. Epub 2014 Mar 4.
39. Hirayama A, Honarpour N, Yoshida M, Yamashita S, Huang F, **Wasserman SM**, Teramoto T. Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk. *Circ J*. 2014 Apr 25;78(5): 1073-82. Epub 2014 Mar 21.
40. Blom DJ, Hala T, Bolognese M, Lillestol MJ, Toth PD, Burgess L, Ceska R, Roth E, Koren MJ, Ballantyne CM, Monsalvo ML, Tsirtsonis K, Kim JB, Scott R, **Wasserman SM**, Stein EA; DESCARTES Investigators. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. *N Engl J Med*. 2014 May 8;370(19): 1809-1819. Epub 2014 Mar 29.
41. Koren MJ, Lundqvist P, Bolognese M, Neutel JM, Monsalvo ML, Yang J, Kim JB, Scott R, **Wasserman SM**, Bays H; MENDEL-2 Investigators. Anti-PCSK9 monotherapy for hypercholesterolemia - the MENDEL-2 randomized, controlled phase 3 clinical trial of evolocumab. *J Am Coll Cardiol*. 2014 Jun 17;63(23): 2531-2540. Epub 2014 Mar 29.
42. Stroes E, Colquhoun D, Sullivan D, Civeira F, Rosenson RS, Watts GF, Bruckert E, Cho L, Dent R, Knusel B, Xue A, Scott R, **Wasserman SM**, Rocco M; GAUSS-2 Investigators. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: The GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. *J Am Coll Cardiol*. 2014 Jun 17;63(23): 2541-2548. Epub 2014 Mar 30.
43. Robinson JG, Nedergaard BS, Rogers WJ, Fialkow J, Neutel JM, Ramstad D, Somaratne R, Legg JC, Nelson P, Scott R, **Wasserman SM**, Weiss R; LAPLACE-2 Investigators. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. *JAMA*. 2014 May 14;311(18): 1870-1882.

44. Marais AD, Kim JB, **Wasserman SM**, Lambert G. PCSK9 inhibition in LDL cholesterol reduction: Genetics and therapeutic implications of very low plasma lipoprotein levels. *Pharmacol Ther.* 2015 Jan;145C: 58-66.
45. Blom DJ, **Wasserman SM**, Stein EA. Evolocumab in hyperlipidemia. *N Engl J Med.* 2014 Aug 28;371(9): 877-878.
46. Ason B, van der Hoorn JW, Chan J, Lee E, Pieterman EJ, Nguyen KK, Di M, Shetterly S, Tang J, Yeh WC, Schwarz M, Jukema JW, Scott R, **Wasserman SM**, Princen HM, Jackson S. PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol and atherosclerosis in the absence of ApoE. *J Lipid Res.* 2014 Nov;55(11): 2370-2379. Epub 2014 Sep 25.
47. Raal F, Stein EA, Dufour R, Turner R, Civeira F, Burgess L, Langslet G, Scott R, Olsson AG, Sullivan D, Hovingh GK, Cariou B, Gouni-Berthold I, Somaratne R, Bridges I, Scott R, **Wasserman SM**, Gaudet D; RUTHERFORD-2 Investigators. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. *Lancet.* 2015 Jan 24;385(9965): 331-340. Epub 2014 Oct 1.
48. Raal FJ, Honarpour N, Blom DJ, Hovingh GK, Xu F, Scott R, **Wasserman SM**, Stein EA; TESLA Investigators. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. *Lancet.* 2015 Jan 24;385(9965): 341-350. Epub 2014 Oct 1.
49. Greenberg BH, Cho W, Saikali KG, Escandón R, Lee JH, Chen MM, Treshkur T, Megreladze I, **Wasserman SM**, Eisenberg P, Malik F, Wolf AA, Shaburishvili T. Safety and tolerability of omecamtiv mecarbil during exercise in patients with ischemic cardiomyopathy and angina. *JACC Heart Fail.* 2015 Jan;3(1): 22-29. Epub 2014 Nov 11.
50. Langslet G, Emery M, **Wasserman SM**. Evolocumab (AMG 145) for primary hypercholesterolemia. *Expert Rev Cardiovasc Ther.* 2015 Mar 31:1-12. Epub 2015 Mar 15.
51. Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, **Wasserman SM**, Scott R, Koren MJ, Stein EA; OSLER Investigators. Open-label study of long-term evaluation against LDL cholesterol (OSLER). *N Engl J Med.* 2015 Apr 16;372(16): 1500-1509. Epub 2015 Mar 15.
52. Fordyce CB, Roe MT, Ahmad T, Libby P, Borer JS, Hiatt WR, Bristow MR, Packer M, **Wasserman SM**, Braunstein N, Pitt B, DeMets DL, Cooper-Arnold K, Armstrong PW, Berkowitz SD, Scott R, Prats J, Galis ZS, Stockbridge N, Peterson ED, Califf RM. Cardiovascular drug development: Is it dead or just hibernating? *J Am Coll Cardiol.* 2015 Apr 21;65(15): 1567-1582.
53. Blom DJ, Djedjos CS, Monsalvo ML, Bridges IM, **Wasserman SM**, Scott RA, Roth EM. Effects of evolocumab on vitamin E and steroid hormone levels: Results from the 52-week, phase 3, double-blind, randomized, placebo-controlled DESCARTES study. *Circ Res.* 2015 Sep 25;117(8): 731-741. Epub 2015 Jul 30.

54. Sabatine MS, **Wasserman SM**, Stein EA. PCSK9 inhibitors and cardiovascular events. *N Engl J Med*. 2015 Aug 20;373(8) :774-775
55. Kiyosue A, Honarpour N, Kurtz C, Xue A, **Wasserman SM**, Hirayama A. A Phase 3 study of evolocumab (AMG 145) in statin-treated Japanese patients at high cardiovascular risk. *Am J Cardiol* 2016 Jan 1;117(1): 40-47. Epub 2015 Oct 19.
56. Sattar N, Preiss D, Robinson JG, Djedjos CS, Elliott M, Somaratne R, **Wasserman SM**, Raal FJ. Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data. *Lancet Diabetes Endocrinol*. 2016 May;4(5): 403-410. Epub 2016 Feb 8.
57. Sabatine MS, Giugliano RP, Keech A, Honarpour N, Wang H, Liu T, **Wasserman SM**, Scott R, Sever PS, and Pedersen TR. Rationale and design of the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) Trial. *Am Heart J* 2016 Mar; 173: 94-101. Epub 2015 Dec 17.
58. Cho L, Rocco M, Colquhoun D, Sullivan D, Rosenson RS, Dent R, Xue A, Scott R, **Wasserman SM**, Stroes E. Clinical profile of statin intolerance in the phase 3 GAUSS-2 study. *Cardiovascular Drugs Ther*. 2016 Jun;30(3): 297-304.
59. Nissen SE, Dent-Acosta RE, Rosenson RS, Stroes E, Sattar N, Preiss D, Mancini GB, Ballantyne CM, Catapano A, Gouni-Berthold I, Stein EA, Xue A, **Wasserman SM**, Scott R, Thompson PD; GAUSS-3 Investigators. Comparison of PCSK9 inhibitor evolocumab vs ezetimibe in statin-intolerant patients: Design of the goal achievement after utilizing an anti-PCSK9 antibody in statin-intolerant subjects 3 (GAUSS-3) Trial. *Clin Cardiol*. Mar 2016; 39(3):137-144. Epub 2016 Mar 4.
60. Teerlink JR, Felker GM, McMurray JV, Ponikowski P, Metra M, Filippatos GS, Ezekowitz JA, Dickstein K, Cleland JGF, Kim JB, Lei L, Knusel B, Wolff AA, Malik FI, **Wasserman SM**. Acute treatment with omecamtiv mecarbil to increase contractility in acute heart failure: The ATOMIC-AHF study. *J Am Coll Cardiol*. 2016 Mar 29; 67: 1444-1455.
61. Nissen SE, Stroes E, Dent-Acosta RE, Rosenson RS, Lehman SJ, Sattar N, Preiss D, Bruckert E, Ceška R, Lepor N, Ballantyne CM, Gouni-Berthold I, Elliott M, Brennan DM, **Wasserman SM**, Somaratne R, Scott R, Stein EA; GAUSS-3 Investigators. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: The GAUSS-3 randomized clinical trial. *JAMA*. 2016 Apr 19;315(15): 1580-1590.
62. Raal FJ, Giugliano RP, Sabatine MS, Koren MJ, Blom D, Seidah NG, Honarpour N, Lira A, Xue A, Chirovolu P, Jackson S, Di M, Peach M, Somaratne R, **Wasserman SM**, Scott R, Stein EA. PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the role of the LDL receptor. *J Lipid Res*. 2016 Jun;57(6): 1086-1096. Epub 2016 Apr 21.
63. Puri R, Nissen SE, Somaratne R, Cho L, Kastelein JJP, Ballantyne CMB, Koenig W, Anderson TJ, Yang J, Kassahun H, **Wasserman SM**, Scott R, Borgman M, Nicholls SJ. Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of GLAGOV (global assessment of plaque regression with a PCSK9 antibody as measured by intravascular ultrasound). *Am Heart J*. 2016 Jun;176: 83-92. Epub 2016 Feb 17.

64. Blom DJ, Koren MJ, Roth E, Monsalvo ML, Djedjos CS, Nelson P, Elliott M, **Wasserman SM**, Ballantyne CM, Holman RR. Evaluation of the efficacy, safety and glycaemic effects of evolocumab (AMG 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome. *Diabetes Obes Metab.* 2017 Jan;19(1): 98-107. Epub 2016 Oct 14.
65. Peach M, Xu R, Fitzpatrick D, Hamilton L, Somaratne R, Scott R, **Wasserman SM**, Djedjos CS. Effect of evolocumab on cholesterol synthesis and absorption. *J Lipid Res.* 2016 Dec;57(12): 2217-2224. Epub 2016 Oct 5.
66. Gibbs JP, Slatter JG, Egbuna O, Geller M, Hamilton L, Dias CS, Xu RY, Johnson J, **Wasserman SM**, Emery MG. Evaluation of evolocumab (AMG 145), a fully human anti-PCSK9 IgG2 monoclonal antibody, in subjects with hepatic impairment. *J Clin Pharmacol.* 2017 Apr;57(4): 513-523. Epub 2016 Oct 26.
67. Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJ, Koenig W, Somaratne R, Kassahun H, Yang J, **Wasserman SM**, Scott R, Ungi I, Podolec J, Ophuis AO, Cornel JH, Borgman M, Brennan DM, Nissen SE. Effect of evolocumab on progression of coronary disease in statin-treated patients: The GLAGOV Randomized Clinical Trial. *JAMA.* 2016 Dec 13;316(22): 2373-2384.
68. Gibbs JP, Doshi S, Kuchimanchi M, Grover A, Emery MG, Dodds MG, Gibbs MA, Somaratne R, **Wasserman SM**, Blom D. Impact of target-mediated elimination on the dose and regimen of evolocumab, a human monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9). *J Clin Pharmacol.* 2017 May;57(5) 616-626. Epub 2016 Nov 15.
69. Watts GF, Chan DC, Dent R, Somaratne R, **Wasserman SM**, Scott R, Burrows S, R Barrett PH. Factorial effects of evolocumab and atorvastatin on lipoprotein metabolism. *Circulation.* 2017 Jan 24;135(4): 338-351. Epub 2016 Dec 9.
70. Desai NR, Giugliano RP, **Wasserman SM**, Gibbs JP, Liu T, Scott R, Sabatine MS. Association between circulating baseline proprotein convertases subtilisin kexin type 9 levels and efficacy of evolocumab. *JAMA Cardiol.* 2017 May 1;2(5): 556-560.
71. Giugliano RP, Mach F, Zavitz K, Kurtz C, Schneider J, Wang H, Keech A, Pedersen TR, Sabatine MS, Sever PS, Honarpour N, **Wasserman SM**, Ott BR; EBBINGHAUS Investigators. Design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy-A cognitive study of patients enrolled in the FOURIER trial. *Clin Cardiol.* 2017 Feb;40(2): 59-65. Epub 2017 Feb 16.
72. Raal FJ, Hovingh GK, Blom D, Santos RD, Harada-Shiba M, Bruckert E, Couture P, Soran H, Watts GF, Kurtz C, Honarpour N, Tang L, Kasichayanula S, **Wasserman SM**, Stein EA. Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study. *Lancet Diabetes Endocrinol* 2017 Apr;5(4): 280-290. Epub 2017 Feb 16.

73. Toth PP, Descamps O, Genest J, Sattar N, Preiss D, Dent R, Djedjos C, Wu Y, Geller M, Uhart M, Somaratne R, **Wasserman SM**; PROFICIO Investigators. Pooled safety analysis of evolocumab in over 6000 patients from double-blind and open-label extension studies. *Circulation*. 2017 May 9;135(19): 1819-1831. Epub 2017 Mar 1.
74. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, **Wasserman SM**, Sever PS, Pedersen TR; FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. *N Engl J Med*. 2017 May 4;376(18): 1713-1722. Epub 2017 Mar 17.
75. Watts GF, Chan DC, Somaratne R, **Wasserman SM**, Sabatine MS. Response by Watts et al to letter regarding article, "Factorial effects of evolocumab and atorvastatin on lipoprotein metabolism". *Circulation*. 2017 Jul 4;136(1): 120-121.
76. Povsic TJ, Scott R, Mahaffey KW, Blaustein R, Edelberg JM, Lefkowitz MP, Solomon SD, Fox JC, Healy KE, Khakoo AY, Losordo DW, Malik FI, Monia BP, Montgomery RL, Riesmeyer J, Schwartz GG, Zelenkofske SL, Wu JC, **Wasserman SM**, Roe MT. Navigating the future of cardiovascular drug development-leveraging novel approaches to drive innovation and drug discovery: Summary of findings from the Novel Cardiovascular Therapeutics Conference. *Cardiovasc Drugs Ther*. 2017 Aug;31(4): 445-458.
77. Giugliano RP, Mach F, Zavitz K, Kurtz C, Im K, Kanevsky E, Schneider J, Wang H, Keech A, Pedersen TR, Sabatine MS, Sever PS, Robinson JG, Honarpour N, **Wasserman SM**, Ott BR; EBBINGHAUS Investigators. Cognitive Function in a Randomized Trial of Evolocumab. *N Engl J Med*. 2017 Aug 17;377(7):633-643.
78. Giugliano RP, Pedersen TR, Park JG, De Ferrari GM, Gaciong ZA, Ceska R, Toth K, Gouni-Berthold I, Lopez-Miranda J, Schiele F, Mach F, Ott BR, Kanevsky E, Pineda AL, Somaratne R, **Wasserman SM**, Keech AC, Sever PS, Sabatine MS; FOURIER Investigators...Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. *Lancet*. 2017 Oct 28;390(10106):1962-1971. Epub 2017 Aug 28.
79. Kasichayanula S, Grover A, Emery MG, Gibbs MA, Somaratne R, **Wasserman SM**, Gibbs JP. Clinical pharmacokinetics and pharmacodynamics of evolocumab, a PCSK9 inhibitor. *Clin Pharmacokinet*. 2018 Jan 20. [Epub ahead of print].
80. **Wasserman SM**, Sabatine MS, Koren MJ, Giugliano RP, Legg JC, Emery MG, Doshi S, Liu T, Somaratne R, Gibbs JP. Comparison of LDL-C reduction using different evolocumab doses and intervals: Biological insights and treatment implications. *J Cardiovasc Pharmacol Ther*. 2018 Jan 1. [Epub ahead of print]
81. Watts GF, Chan DC, Somaratne R, **Wasserman SM**, Scott R, Marcovina SM, Barrett PHR. Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics. *Eur Heart J*. 2018 Mar 16. [Epub ahead of print].
82. Graham I, Shear C, De Graeff P, Boulton C, Catapano AL, Stough WG, Carlsson SC, De Backer G, Emmerich J, Greenfeder S, Kim AM, Lautsch D, Nguyen T, Nissen SE, Prasad K, Ray KK, Robinson JG, Sasiela WJ, Bruins Slot K, Stroes E, Thuren T, Van der Schueren B, Velkovski-Rouyer M, **Wasserman SM**, Wiklund O, Zouridakis E; European

Society of Cardiology Cardiovascular Roundtable. New strategies for the development of lipid-lowering therapies to reduce cardiovascular risk. *Eur Heart J Cardiovasc Pharmacother.* 2018 Apr 1;4(2):119-127.

83. Raman SR, Curtis LH, Temple R, Andersson T, Ezekowitz J, Ford I, James S, Marsolo K, Mirhaji P, Rocca M, Rothman RL, Sethuraman B, Stockbridge N, Terry S, **Wasserman SM**, Peterson ED, Hernandez AF. Leveraging electronic health records for clinical research. *Am Heart J.* 2018 Apr 30;202:13-19. [Epub ahead of print]
84. Kuchimanchi M, Grover A, Emery MG, Somaratne R, **Wasserman SM**, Gibbs JP, Doshi S. Population pharmacokinetics and exposure-response modeling and simulation for evolocumab in healthy volunteers and patients with hypercholesterolemia. *J Pharmacokinet Pharmacodyn.* 2018 May 7. [Epub ahead of print]
85. Chan DC, Watts GF, Somaratne R, **Wasserman SM**, Scott R, Barrett PHR. Comparative effects of PCSK9 (proprotein convertase subtilisin/kexin type 9) and statins on postprandial triglyceride-rich lipoprotein metabolism. *Arterioscler Thromb Vasc Biol.* 2018 Jun 7. [Epub ahead of print]

Book chapters

1. Yang E, **Wasserman SM**, Ishida T, Tabibiazar R and Quertermous T. (2002). Molecular biology applications in cardiovascular medicine. In: M.S. Runge and C. Patterson (eds.), Principles of Molecular Cardiology. 1st edition. Totowa, NJ: Humana Press Inc.
2. **Wasserman SM** and Topper JN. (2006). Endothelium in health and disease. In: M.A. Creager, V. Dzau, and J. Loscalzo (eds.), Vascular Medicine, A Companion to Braunwald's Heart Disease. 1st edition. Philadelphia, PA: Elsevier Science.